相关实验视频

Updated: Jul 19, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在接受新辅助化疗治疗的HER2-低和HER2-零早期乳腺癌中,病理完整反应和生存率

Silvia Mihaela Ilie¹, Nathalie Briot², Guillaume Constantin²

¹Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, 1 Rue du Professeur Marion, 21000, Dijon, France.

Breast cancer (Tokyo, Japan)

|August 10, 2023

概括

在接受新辅助化疗时,低HER2乳腺癌的化学敏感性和预后与HER2-0瘤相似,无论激素受体状态如何. 这一发现对于了解早期乳腺癌 (eBC) 治疗结果至关重要.

科学领域:

在瘤学瘤学.
分子诊断学分子诊断学
临床研究临床研究

背景情况:

由HER2表达而没有放大而定义的低HER2乳腺癌,代表了一个独特的临床实体.
鉴定HER2-低瘤的特征对于了解治疗敏感性和患者预后至关重要.

研究的目的:

与HER2-0瘤相比,研究HER2-低早期乳腺癌 (eBC) 的化学敏感性和长期预后.
分析与病理完整反应 (pCR) 和HR+和HR-eBC患者的存活率相关的因素.

主要方法:

在2007年至2018年期间,对511名接受新辅助化疗 (NAC) 的eBC患者进行了回顾性分析.
根据激素受体 (HR) 状态分层的HER2-low和HER2-0组之间的临床病理学特征,治疗反应和生存数据的比较.

主要成果:

在HR+或HR-eBC中,HER2状态 (低与0) 与pCR没有独立相关.
在HR+eBC中,在HER2-低和HER2-0瘤之间,无复发存活率 (RFS) 和整体存活率 (OS) 并没有显著差异.
在HR-eBC中,通过单变量分析,RFS和OS在HER2-0瘤中略有改善,但在多变量分析中,这种差异并不显著.

结论:

在接受NAC的eBC患者中,HER2低瘤的化学敏感性和预后与HER2-0瘤相似.
激素受体表达亚型和其他临床病理特征是评估低HER2乳腺癌结果时的重要考虑因素.

关键词:

乳腺癌乳腺癌乳腺癌在HER2的低水平下,在HER2中,HER2为零.新辅助化学疗法新辅助化学疗法病理学完整的反应反应.

更多相关视频

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...